2026-06-14T03:29:10Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/65802024-09-27T09:53:11Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Baar, Marjolein P. author Perdiguero, Eusebio author Munoz-Canoves, Pura author de Keizer, Peter L. J. author 2018 Aging is the prime risk factor for the broad-based development of diseases. Frailty is a phenotypical hallmark of aging and is often used to assess whether the predicted benefits of a therapy outweigh the risks for older patients. Senescent cells form as a consequence of unresolved molecular damage and persistently secrete molecules that can impair tissue function. Recent evidence shows senescent cells can chronically interfere with stem cell function and drive aging of the musculoskeletal system. In addition, targeted apoptosis of senescent cells can restore tissue homeostasis in aged animals. Thus, targeting cellular senescence provides new therapeutic opportunities for the intervention of frailty-associated pathologies and could have pleiotropic health benefits. Curr Opin Pharmacol. 2018; 40:147-155 10.1016/j.coph.2018.05.007 1471-4973 1471-4892 Current Opinion in Pharmacology 29883814 http://hdl.handle.net/20.500.12105/6580 MESENCHYMAL STEM-CELLS SKELETAL-MUSCLE REGENERATION MARROW STROMAL CELLS CELLULAR SENESCENCE SATELLITE CELLS KNEE OSTEOARTHRITIS ARTICULAR-CARTILAGE PROGENITOR CELLS DNA-DAMAGE POSTTRAUMATIC OSTEOARTHRITIS Musculoskeletal senescence: a moving target ready to be eliminated